Bayer, Onyx submit cancer drug Nexavar for U.S., EU approval

07/3/2013 | Pharmaceutical Business Review Online

Bayer HealthCare and Onyx Pharmaceuticals have filed regulatory applications with the FDA and the European Medicines Agency for approval to market Nexavar, or sorafenib, as a treatment for locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The applications were based on data from a late-stage trial showing that the drug significantly improved progression-free survival compared with a placebo.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD